Vemurafenib-induced neutrophilic panniculitis: A new case and review of the literature

American Journal of Dermatopathology

Volumn 38, Issue 7, 2016, Pages e93-e96

  Vázquez Osorio, Igor ^a   Sánchez Aguilar, María Dolores ^a   García Rodiño, Sara ^a   Suárez Peñaranda, José M ^a   Aliste, Carlos ^a   Vázquez Veiga, Hugo ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

BRAF; Drug reaction; Metastatic melanoma; Panniculitis; Vemurafenib

Indexed keywords

ALPHA2B INTERFERON; B RAF KINASE; VEMURAFENIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; SULFONAMIDE;

ADULT; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CELL INFILTRATION; DRUG MEGADOSE; FAT NECROSIS; FEMALE; GENE MUTATION; HISTIOCYTE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATORY CELL; LYMPHOCYTE; METASTATIC MELANOMA; MIDDLE AGED; NEUTROPHIL; NEUTROPHILIC PANNICULITIS; PANNICULITIS; PLASMA CELL; PRIORITY JOURNAL; RETICULAR DERMIS; SKIN BIOPSY; SKIN METASTASIS; SUBCUTANEOUS NODULE; TREATMENT RESPONSE; TUMOR BIOPSY; BIOPSY; CHEMICALLY INDUCED; DRUG EFFECTS; LOWER LIMB; MELANOMA; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; SECONDARY; SKIN NEOPLASMS;

ANTINEOPLASTIC AGENTS; BIOPSY; FEMALE; HUMANS; INDOLES; LOWER EXTREMITY; MELANOMA; MIDDLE AGED; NEUTROPHIL INFILTRATION; NEUTROPHILS; PANNICULITIS; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84960155368     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0000000000000528     Document Type: Article

References (21)

1. Sharma A, Shah SR, Illum H, et al. Vemurafenib: Targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies. Drugs. 2012;72: 2207-2222.
2. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364: 2507-2516.
3. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Eng J Med. 2012;366: 707-714.
4. Sinha R, Edmonds K, Newton-Bishop JA, et al. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: Practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol. 2012;167: 987-994.
5. Boussemart L, Routier E, Mateus C, et al. Prospective study of cuatenous side-effects associated with the BRAF inhibitor vemurafenib: A study of 42 patients. Ann Oncol. 2013;24: 1691-1697.
6. Chu EY, Wanat KA, Miller CJ, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study. J Am Acad Dermatol. 2012;67: 1256-1272.
7. Chan MP. Neutrophilic panniculitis: Algorithmic approach to a heterogeneous group of disorders. Arch Pathol Lab Med. 2014;138: 1337-1343.
8. Sutra-Loubet C, Carlotti A, Guillemett J, et al. Neutrophilic panniculitis. J Am Acad Dermatol. 2004;50: 280-285.
9. Zimmer L, Livingstone E, Hillen U, et al. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol. 2012;148: 357-361.
10. Monfort JB, Pagès C, Schneider P, et al. Vemurafenib-induced neutrophilic panniculitis. Melanoma Res. 2012;22: 399-401.
11. Novoa RA, Honda K, Koon HB, et al. Vasculitis and panniculitis associated with vemurafenib. J Am Acad Dermatol. 2012;67: E271-e272.
12. Villani AP, Zaharia D, Dalle S, et al. Vemurafenib-induced panniculitis. Eur J Dermatol. 2013;23: 258-260.
13. Kim GH, Levy A, Compoginis G. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib. J Cutan Pathol. 2013;40: 667-669.
14. Sinha R, Edmonds K, Newton-Bishop J, et al. Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib. J Clin Oncol. 2013;31: E320-e321.
15. Maldonado-Seral C, Berros-Fombella JP, Vivanco-Allende B, et al. Vemurafenib- Associated neutrophilic panniculitis: An emergent adverse effect of variable severity. Dermatol Online J. 2013;19: 16.
16. Degen A, Volker B, Kapp A, et al. Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma. Eur J Dermatol. 2013;23: 118.
17. Chaminade A, Conte H, Jouary T, et al. BRAF inhibitors-induced panniculitis: A cutaneous side effect mimicking subcutaneous melanoma metastasis. J Eur Acad Dermatol Venereol. 2015;29: 392-393.
18. Mössner R, Zimmer L, Berking C, et al. Eryhema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature. J Eur Acad Dermatol Venereol. 2015;29: 1797-1806.
19. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417: 949-954.
20. Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: A meta-analysis. Br J Dermatol. 2011;164: 776-784.
21. Choy B., Chou S., Anforth R., et al.Panniculitis in patients treated with BRAF inhibitors: A case series Am J Dermatopathol 2014 36493-497